Results 121 to 130 of about 8,086 (190)

No differences in miRNA expression in the stroma of ERG+ and ERG– prostate cancers

Polish Journal of Pathology
Prostate cancer (PC) is one of the most common cancers in males. A significant proportion of PCs bear TMPRSS2-ETS translocation and overexpress ERG transcription factor, allowing classification into ERG+ and ERG– groups, which differ in several features ...
Gracjan Wątor, Maria Kołton-Wróż, Paweł Wołkow, Łukasz Bełch, Piotr Chłosta, Joanna Szpor, Agnieszka Klimkowska, Katarzyna Nejman, Alicja Józkowicz, Aleksandra Piechota-Polańczyk, Krzysztof Okoń   +10 more
doaj   +1 more source

Drugging the Cancers Addicted to DNA Repair [PDF]

, 2017
Defects in DNA repair can result in oncogenic genomic instability. Cancers occurring from DNA repair defects were once thought to be limited to rare inherited mutations (such as BRCA1 or 2).
Hromas, Robert, Jones, Dennie, Lee, Suk-Hee, Nickoloff, Jac A., Williamson, Elizabeth A.   +4 more
core   +1 more source

Predicting prostate cancer : on the use of biomarkers in prostate cancer diagnostics [PDF]

, 2015
Aims The aims of this thesis work were to answer the following questions. Paper I: How prevalent is testing and retesting with prostate-specific antigen (PSA)?; Paper II: Is a genetic score based on single-nucleotide polymorphisms (SNPs) informative
Nordström, Tobias
core   +1 more source

Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer [PDF]

, 2017
Felisbino S. received a fellowship from the Sao Paulo Research Foundation (FAPESP) ref. 2013/08830-2 and 2013/06802-1. Anne Y Warren research time funded by: Cambridge Biomedical Research Centre.Monocarboxylate Transporter 2 (MCT2) is a major pyruvate ...
Felisbino, Sergio, Fryer, Lee, Kay, Jonathan, Lynch, Andy G., Massie, Charles E., Neal, David E., Pértega-Gomes, Nelma, Shaw, Greg, Vizcaino, Jose R., Warren, Anne Y., Whitaker, Hayley   +10 more
core   +1 more source

Handheld ISFET Lab-on-Chip detection of TMPRSS2-ERG and AR mRNA for prostate cancer prognostics. [PDF]

IEEE Sens Lett, 2023
Broomfield J, Kalofonou M, Franklin S, Powell SM, Pataillot-Meakin T, Moser N, Bevan CL, Georgiou P.   +7 more
europepmc   +1 more source

Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer

, 2013
Early-onset prostate cancer (EO-PCA) represents the earliest clinical manifestation of prostate cancer. To compare the genomic alteration landscapes of EO-PCA with "classical" (elderly-onset) PCA, we performed deep sequencing-based genomics analyses in ...
Amschler, N., Amstislavskiy, V., Avci, M., Baer, C., Bartholomae, C., Benes, V., Bogatyrova, O., Brors, B., Burkhardt, L., Claus, R., Eils, J., Eils, R., Falth, M., Feuerbach, L., Gade, S., Galal, R., Gerhauser, C., Gjoni, J., Graefen, M., Grupp, K., Gu, L., Hass, T., Huang, P., Huland, H., Hutter, B., Jager, N., Kabbe, R., Kluth, M., Korbel, J., Krohn, A., Kuner, R., Lawerenz, C., Lehrach, H., Mader, M., Masser, S., Minner, S., Parkhomchuk, D., Plass, C., Radomski, S., Raeder, B., Rausch, T., Sauter, G., Schlangen, K., Schlomm, T., Schmidt, M., Simon, R., Sirma, H., Stehr, H., Steurer, S., Stumm, L., Stutz, A., Sultan, M., Sultmann, H., von Kalle, C., Warnatz, H., Weichenhan, D., Weischenfeldt, J., Wuttig, D., Yaspo Lehrach, M., Zichner, T.   +59 more
core   +1 more source

Optical coding of fusion genes using multicolor quantum dots for prostate cancer diagnosis

International Journal of Nanomedicine, 2017
Hyojin Lee,1,* Chloe Kim,2,* Dongjin Lee,1,3,* Jea Ho Park,1,2 Peter C Searson,2 Kwan Hyi Lee1,3 1Center for Biomaterials, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea; 2Department of ...
Lee H, Kim C, Lee D, Park JH, Searson PC, Lee KH   +5 more
doaj  

Transcriptome Profiling of Prostate Cancer, Considering Risk Groups and the TMPRSS2-ERG Molecular Subtype. [PDF]

Int J Mol Sci, 2023
Kobelyatskaya AA, Pudova EA, Katunina IV, Snezhkina AV, Fedorova MS, Pavlov VS, Kotelnikova AO, Nyushko KM, Alekseev BY, Krasnov GS, Kudryavtseva AV.   +10 more
europepmc   +1 more source

Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer. [PDF]

Mol Cancer Ther, 2023
Li C, Zhang J, Wu Q, Kumar A, Pan G, Pan G, Kelvin DJ.   +6 more
europepmc   +1 more source

Differential Effect of Non-Steroidal Anti-Inflammatory Drugs Aspirin and Naproxen against TMPRSS2-ERG (Fusion)-Driven and Non-Fusion-Driven Prostate Cancer. [PDF]

Cancers (Basel), 2023
Raina K, Kandhari K, Kant R, Prasad RR, Mishra N, Maurya AK, Fox JT, Sei S, Shoemaker RH, Bosland MC, Maroni P, Agarwal C, Agarwal R.   +12 more
europepmc   +1 more source